Cognitive · In Clinical Trials
Intranasal Insulin
No lawful US pathway
01 · Overview
Intranasal insulin involves the administration of regular human insulin via nasal spray to target central nervous system insulin receptors while minimizing peripheral metabolic effects (PMID 41436338). Insulin itself is an FDA-approved drug for diabetes, but intranasal use for cognition is not an approved indication.
Brain insulin signaling has been linked to synaptic function and Alzheimer disease pathology, providing a rationale for study in mild cognitive impairment and Alzheimer disease. In rats, intranasally applied insulin reached deep brain structures within 15 minutes and activated Akt survival signaling in dopaminergic neurons (PMID 30762017).
02 · Research summary & key findings
A 4-month pilot randomized trial in 104 adults with amnestic mild cognitive impairment or Alzheimer disease reported improved delayed memory with the lower dose and preserved caregiver-rated function (PMID 21911655). However, the larger 12-month multisite phase 2/3 trial found no cognitive or functional benefit over placebo in its primary analysis (PMID 32568367), and a 2026 meta-analysis of five randomized trials (540 participants) found no meaningful cognitive, functional, or CSF biomarker improvements, though treatment was generally well tolerated (PMID 41436338). A small 4-week phase 2 trial reported favorable cognitive composite and biomarker signals, and its authors called for a longer, larger trial (PMID 41057918).
03 · Regulatory status
Intranasal Insulin is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
No lawful pathway today
Intranasal Insulin is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for cognitive support?
Intranasal Insulin is still in clinical trials, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on cognitive support, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Intranasal
References
- [1]Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial Arch Neurol, 2012. PMID 21911655
- [2]Rapid transport of insulin to the brain following intranasal administration in rats Neural Regen Res, 2019. PMID 30762017
- [3]Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial JAMA Neurol, 2020. PMID 32568367
- [4]A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD Alzheimers Dement, 2025. PMID 41057918
- [5]Intranasal insulin for mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials Rev Neurol (Paris), 2026. PMID 41436338
Primary literature
- PubMed: "Intranasal Insulin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Intranasal Insulin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Intranasal Insulin"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Cognitive
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.